Press releases

Press release 2024/01/23

Medivir invites to a conference call today on updated data at ASCO GI and the plans moving forward for fostrox in primary liver cancer (HCC)

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Press release 2024/01/22 Regulatory

Medivir carries out a directed share issue of approx. SEK 20 million

INSIDER INFORMATION: Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) (“Medivir” or the “Company”), a pharmaceutical company focused on developing innovative...

Press release 2024/01/17

Fostrox + Lenvima shows further improved response rates and time to progression in advanced liver cancer (HCC) at ASCO GI Symposium

Overall Response Rate (ORR) has increased to 25% (local review RECIST 1.1) Median time to progression continues to improve as data...

Press release 2024/01/15

Medivir to present clinical pharmacokinetic data at EASL Liver Cancer Summit further supporting the continued development of fostrox

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

Press release 2024/01/04

Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study